Arrowhead Pharmaceuticals, Inc. · XETR:HDP1

Arrowhead Pharmaceuticals, Inc. financial statements

Arrowhead Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue450.8M829.4M3.55M240.7M243.2M138.3M88.0M168.8M16.1M31.4M
Cost of revenue23.9M18.6M12.5M10.4M67.4M63.7M
Gross profit829.4M-15.0M228.2M243.2M138.3M88.0M168.8M16.1M31.4M
Research and development739.1M607.2M505.9M353.2M297.3M206.3M128.9M81.0M53.0M50.9M
Selling, general and administrative202.0M123.9M98.8M90.9M124.4M81.0M52.3M26.6M19.1M17.5M
Operating income-707.2M98.3M-601.1M-205.0M-178.5M-149.0M-93.2M61.2M-55.9M-37.0M
Depreciation and amortization24.7M22.2M16.9M10.7M8.70M6.60M4.20M2.70M3.00M2.99M
EBITDA-682.5M120.5M-584.2M-194.3M-169.8M-142.4M-89.0M63.9M-52.9M-34.0M
Interest expense93.7M89.4M32.4M18.3M009.19B6.96B1.05B415.1M
Income before tax-723.9M51.5M-612.5M-206.5M-172.7M-140.8M-84.6M68.1M-54.4M-34.4M
Income tax-6.78M21.4M-2.77M2.78M3.79M2.00K2.00K174.0K2.40K2.40K
Net income-724.2M-1.63M-599.5M-205.3M-176.1M-140.8M-84.6M68.0M-54.5M-34.4M
Earnings per share, basic-5.11-0.01-5.00-1.92-1.67-1.36-0.840.72-0.65-0.47
Earnings per share, diluted-5.11-0.01-5.00-1.92-1.67-1.36-0.840.69-0.65-0.47

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents62.7M226.5M102.7M110.9M108.0M184.4M143.6M221.8M30.1M24.8M
Short-term investments1.13B692.8M578.3M292.7M0126.7M85.0M36.9M46.4M40.8M
Receivables9.93M6.82M001.41M10.3M846.0K661.4K327.4K67.8K
Inventory9.07M0-21.6M4.36M4.25M3.32M1.27M867.4K
Current assets1.29B950.6M695.5M416.5M405.3M384.6M322.4M265.2M78.8M67.9M
Property, plant and equipment371.3M382.5M386.0M290.3M110.3M48.7M30.9M23.2M13.9M15.5M
Goodwill15.4M17.1M18.8M20.5M
Total assets1.74B1.39B1.14B765.6M691.9M710.1M522.5M349.8M111.6M104.0M
Accounts payable30.1M17.7M11.4M35.9M2.87M9.46M6.83M7.65M2.81M4.08M
Current liabilities311.3M195.5M103.2M105.5M138.8M146.5M40.7M97.1M12.4M18.7M
Long-term debt214.9M393.2M2.10M2.33M
Total debt366.3M851.9M383.5M81.6M25.5M21.1M2.33M2.53M
Total liabilities881.9M948.7M478.4M273.6M301.3M60.7M105.8M16.4M23.2M
Shareholders' equity50.3M466.1M185.4M271.3M398.5M408.8M461.8M244.6M95.8M81.4M
Shares outstanding141.3M135.7M124.4M107.3M106.0M104.3M102.4M95.5M88.5M74.8M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-271.9M179.6M-462.9M-153.9M-136.1M171.3M-95.8M173.0M-47.2M-23.9M
Capital spending-12.0M-22.7M-141.5M-176.7M-52.8M-23.6M-12.0M-12.0M-1.42M-7.92M
Free cash flow-283.9M156.9M-604.3M-330.6M-188.9M147.7M-107.8M161.0M-48.6M-31.9M
Cash from investing-670.5M-129.3M-420.1M-96.2M-5.42M-141.7M-240.8M-47.7M-7.43M-48.6M
Cash from financing776.8M74.0M870.5M253.1M65.2M11.3M257.9M66.4M60.0M12.1M
Dividends paid00
Share buybacks5.19M11.3M257.9M68.8M-54.7K-438.8K
Change in cash-165.6M124.3M-12.4M3.01M-76.4M40.9M-78.2M191.7M5.29M-60.5M